-
公开(公告)号：US08258284B2
公开(公告)日：2012-09-04
申请号：US12777042
申请日：2010-05-10
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
IPC分类号： C07H21/04
CPC分类号： C12Q1/6883 , C12Q2600/158 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.
摘要翻译： 本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。 本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。 使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和 蛋白质。 本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。 本发明还提供了鉴定使用本发明的生物标志物的产物在鉴定精神分裂症和/或双相性精神障碍的新型治疗靶标的方法，以及筛选所述生物标志物的基因以获得另外的疾病标志物的方法。
-
公开(公告)号：US20090098564A1
公开(公告)日：2009-04-16
申请号：US12287629
申请日：2008-10-10
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/158 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.
摘要翻译： 本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并且可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。 本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。 使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和 蛋白质。 本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。 本发明还提供了鉴定使用本发明的生物标志物的产物在鉴定精神分裂症和/或双相性精神障碍的新型治疗靶标的方法，以及筛选所述生物标志物的基因以获得另外的疾病标志物的方法。
-
3.发明申请Computer system and methods for constructing biological classifiers and uses thereof 失效用于构建生物分类器的计算机系统和方法及其用途公开(公告)号：US20070269804A1
公开(公告)日：2007-11-22
申请号：US10568264
申请日：2005-06-20
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
摘要： The present invention provides systems and method for constructing classifiers that distinguish between trait subgroups using molecular marker data from blood samples. The invention further encompasses the use of the classifiers and combinations of molecular markers identified by the classifiers in a wide variety of applications including: diagnosis; prognosis; prediction of disease, stage of disease or disease risk; monitoring disease progression and/or regression; monitoring disease reoccurrence and identifying risk of disease reoccurrence; determining and/or predicting response to treatment and/or treatment outcomes; monitoring and/or predicting treatment compliance or non compliance and the like. The invention further provides a variety of selected molecular markers and a means to identify combinations of the selected molecular markers useful for diagnosing particular traits of interest.
摘要翻译： 本发明提供用于构建分类器的系统和方法，其使用来自血液样品的分子标记数据区分特征亚组。 本发明还包括在各种应用中使用分类器和由分类器鉴定的分子标记物的组合，包括：诊断; 预后; 疾病预测，疾病阶段或疾病风险; 监测疾病进展和/或消退; 监测疾病复发并发现疾病复发的风险; 确定和/或预测对治疗和/或治疗结果的反应; 监测和/或预测治疗依从性或不合规等。 本发明进一步提供了多种选择的分子标记和识别用于诊断感兴趣的特定性状的所选分子标记物的组合的方法。
-
公开(公告)号：US20060263797A1
公开(公告)日：2006-11-23
申请号：US11347944
申请日：2006-02-06
申请人： Choong-Chin Liew , Hongwei Zhang , Adam Dempsey , Thomas Yager , Samuel Chao
发明人： Choong-Chin Liew , Hongwei Zhang , Adam Dempsey , Thomas Yager , Samuel Chao
IPC分类号： C12Q1/68 , G01N33/567 , G01N33/53
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N2800/102
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.
摘要翻译： 本发明涉及新生物标志物的鉴定和选择以及与没有骨关节炎的个体相比，在具有轻度骨关节炎的个体中差异表达的新型生物标志物组合的鉴定和选择。 与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质也包括在本发明的范围内，如含有用于诊断轻度骨关节炎的所述多核苷酸和蛋白质的试剂盒。 本发明进一步包括使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质，以监测个体的疾病回归并监测治疗方案的功效。 本发明还提供了使用本发明的生物标志物的产物鉴定骨关节炎的新型治疗靶标的方法。
-
公开(公告)号：US20130165336A1
公开(公告)日：2013-06-27
申请号：US13603094
申请日：2012-09-04
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
IPC分类号： G01N21/64
CPC分类号： C12Q1/6883 , C12Q2600/158 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens.
摘要翻译： 本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并且可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。 本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。 使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和 蛋白质。 本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。
-
公开(公告)号：US08142998B2
公开(公告)日：2012-03-27
申请号：US12554141
申请日：2009-09-04
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao , Hongwei Zhang , Wayne Marshall
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao , Hongwei Zhang , Wayne Marshall
CPC分类号： G01N33/564 , C12N15/113 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2310/15 , C12Q1/6883 , C12Q2600/158 , G01N2800/105 , G01N2800/52
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and/or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The measurement of expression of the products of the biomarkers and combinations of biomarkers demonstrates particular advantage in one or more of the following: (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of OA. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers are within the scope of the invention as are kits containing the polynucleotides and proteins and the use of the polynucleotides and proteins. The biomarker products can be used to identify therapeutic targets for osteoarthritis, and compounds that bind and/or modulate gene activity.
摘要翻译： 本发明涉及新型生物标志物的鉴定和选择以及在骨关节炎和/或在骨关节炎的特定阶段中差异表达的新型生物标志物组合的鉴定和选择，以及选择新型生物标志物组合的方法。 测量生物标志物的产物和生物标志物的组合在以下一个或多个中表现出特别的优点：（a）诊断个体具有关节炎，（b）区分两个阶段的骨关节炎（OA）和（c） 诊断个人具有特定的OA阶段。 与生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质在本发明的范围内，以及含有多核苷酸和蛋白质的试剂盒以及多核苷酸和蛋白质的用途。 生物标记产物可用于鉴定骨关节炎的治疗靶点，以及结合和/或调节基因活性的化合物。
-
公开(公告)号：US20100143916A1
公开(公告)日：2010-06-10
申请号：US12554141
申请日：2009-09-04
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao , Hongwei Zhang , Wayne Marshall
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao , Hongwei Zhang , Wayne Marshall
IPC分类号： C12Q1/68
CPC分类号： G01N33/564 , C12N15/113 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2310/15 , C12Q1/6883 , C12Q2600/158 , G01N2800/105 , G01N2800/52
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and/or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The measurement of expression of the products of the biomarkers and combinations of biomarkers of the invention demonstrates particular advantage in one or more of the following: (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of osteoarthritis (OA). As would be understood, in order to measure the products of biomarkers of the invention, polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of osteoarthritis (OA). Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease progression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of compounds that bind and/or modulate the activity of the genes of the invention. The compounds identified via such methods are useful for the development of assays to study osteoarthritis and osteoarthritis progression. Further, the compounds identified via such methods are useful as lead compounds in the development of prophylactic and therapeutic compositions for the prevention, treatment, management and/or amelioration of osteoarthritis or a symptom thereof.
-
公开(公告)号：US07713695B2
公开(公告)日：2010-05-11
申请号：US11347944
申请日：2006-02-06
申请人： Choong-Chin Liew , Hongwei Zhang , Adam Dempsey , Thomas Yager , Samuel Chao
发明人： Choong-Chin Liew , Hongwei Zhang , Adam Dempsey , Thomas Yager , Samuel Chao
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N2800/102
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.
摘要翻译： 本发明涉及新生物标志物的鉴定和选择以及与没有骨关节炎的个体相比，在具有轻度骨关节炎的个体中差异表达的新型生物标志物组合的鉴定和选择。 与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质也包括在本发明的范围内，如含有用于诊断轻度骨关节炎的所述多核苷酸和蛋白质的试剂盒。 本发明进一步包括使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质，以监测个体的疾病回归并监测治疗方案的功效。 本发明还提供了使用本发明的生物标志物的产物鉴定骨关节炎的新型治疗靶标的方法。
-
公开(公告)号：US08483968B2
公开(公告)日：2013-07-09
申请号：US12777140
申请日：2010-05-10
申请人： Choong-Chin Liew , Hongwei Zhang , Adam Dempsey , Thomas Yager , Samuel Chao
发明人： Choong-Chin Liew , Hongwei Zhang , Adam Dempsey , Thomas Yager , Samuel Chao
IPC分类号： G01N33/48
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N2800/102
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.
摘要翻译： 本发明涉及新生物标志物的鉴定和选择以及与没有骨关节炎的个体相比，在具有轻度骨关节炎的个体中差异表达的新型生物标志物组合的鉴定和选择。 与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质也包括在本发明的范围内，如含有用于诊断轻度骨关节炎的所述多核苷酸和蛋白质的试剂盒。 本发明进一步包括使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质，以监测个体的疾病回归并监测治疗方案的功效。 本发明还提供了使用本发明的生物标志物的产物鉴定骨关节炎的新型治疗靶标的方法。
-
公开(公告)号：US20050208519A1
公开(公告)日：2005-09-22
申请号：US10989191
申请日：2004-11-15
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
CPC分类号： C12Q1/6883 , C12Q2600/158 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.
摘要翻译： 本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并且可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。 本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。 使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和 蛋白质。 本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。 本发明还提供了鉴定使用本发明的生物标志物的产物在鉴定精神分裂症和/或双相性精神障碍的新型治疗靶标的方法，以及筛选所述生物标志物的基因以获得另外的疾病标志物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
75 条记录 (耗时 0.061 秒)
